About enVVeno Medical
enVVeno Medical is a publicly listed company based in Irvine (United States) founded in 1999 by Norman Jaffe. The company has 37 employees. Its chief executive, as recorded, is Robert Berman. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its competitors include Tactile Medical, DeVoro Medical and Micro Medical Solutions; 3 of its 3 listed competitors have raised funding.
Company details
Developer of medical device for the the treatment of venous diseases. The company is focused on the development of bioprosthetic solutions VenoValve an implant for the treatment of deep venous chronic venous insufficiency to assist in propelling blood up the leg, and back to the heart and lungs.
- Headquarters Irvine, United States
- Employees 37
- Founders Norman Jaffe
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website envveno.com
- Social LinkedIn X Facebook
- Net Profit-$19.47 M (USD)10.76as on Dec 31, 2025
- EBITDA-$20.41 M (USD)12.4as on Dec 31, 2025
- Latest Funding Round$28M (USD), Post-IPO
Oct 2023
- InvestorsPerceptive Advisors
& 4 more
- Employee Count37
Funding Insights of enVVeno Medical
- Total Rounds 6
- Last Round Post-IPO — $28M
- First Round $680,000
(Dec 2015)
- Investors Count 5
All 6 funding rounds of enVVeno Medical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2023 | $28M | Post-IPO | – | – | |
| Aug 2020 | $1.56M | Post-IPO | – | – | – |
| Mar 2020 | $650,000 | Post-IPO | – | – | – |
| May 2019 | $2.7M | Post-IPO | – | – | – |
| Mar 2017 | $194,000 | Unspecified | – | – | – |
| Dec 2015 | $680,000 | Unspecified | – | – | – |
5 investors in total: 5 institutional.
Investors in enVVeno Medical
enVVeno Medical has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Perceptive Advisors, L1 Capital and Nantahala Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
| velancapital.com | ||||
Fundamentally-driven firm investing in micro-cap stocks with long and short strategies. | 2004 | nantahalapartners.com | New Canaan, United States | |
Provides alternative investment management services as a SEC-regulated advisory firm. | 1983 | kingdon.com | New York, United States | |
Long/short equity strategies are utilized by this Australian hedge fund. | 2007 | l1.com.au | Melbourne, Australia |
Investor details for enVVeno Medical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of enVVeno Medical
2 people are tracked at enVVeno Medical (2 in leadership); the tracked headcount is 37.
| Name | Role | Group |
|---|---|---|
Norman Jaffe | Founder | Leadership |
Robert Berman | CEO | Leadership |
Complete people profiles for enVVeno Medical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of enVVeno Medical
enVVeno Medical is a publicly listed company on the NASDAQ with ticker symbol NVNO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date10 Feb 2021
- Listed onOTCMKTS: NVNBW
- Listed entityenVVeno Medical Corporation
- Exchange sectorHealth technology
Timeline of enVVeno Medical
4 dated milestones of enVVeno Medical across 24 years, from founding to its latest funding, stage changes and deals.
- Founded enVVeno Medical is founded.
- Funding First funding round of $680K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $28.0M.
Competitors of enVVeno Medical
enVVeno Medical has 3 listed competitors in our database, 3 of them funded. They include Tactile Medical, DeVoro Medical and Micro Medical Solutions.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tactilemedical.com | 1995 | Minneapolis, United States | $23.2M | 592 | Home therapy devices for lymphedema and venous ulcers are provided. | |
| devoromedical.com | 2018 | Fremont, United States | $18M | Medical devices for treating cardiac diseases are developed. | ||
| micromedicalsolutions.net | 2014 | Wilmington, United States | $15.48M | Developer of a device for CLI and PAD patients to prevent amputation |
Detailed competitors of enVVeno Medical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of enVVeno Medical
The website of enVVeno Medical (envveno.com) receives about 5.2K visits a month.
- Monthly visits5.2K
▼ 7.8% vs previous month
Websites whose visitors overlap most with enVVeno Medical. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
venovalve.com | venovalve.com | 100% | #12,992,097 | – |
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as enVVeno Medical (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Envveno Medical
Complete news archive for enVVeno Medical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about enVVeno Medical
enVVeno Medical was founded in 1999 and raised its 1st funding round 16 years after it was founded.
enVVeno Medical is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Robert Berman is the CEO of enVVeno Medical, as recorded in our data.
enVVeno Medical has 37 employees.
Developer of medical device for the the treatment of venous diseases. The company is focused on the development of bioprosthetic solutions VenoValve an implant for the treatment of deep venous chronic venous insufficiency to assist in propelling blood up the leg, and back to the heart and lungs.
enVVeno Medical's top competitors include Tactile Medical, Micro Medical Solutions and DeVoro Medical.
Yes, enVVeno Medical is publicly traded on NASDAQ under the ticker symbol NVNO.
enVVeno Medical has 5 investors. Key investors include Perceptive Advisors, L1 Capital, Nantahala Capital Management, Kingdon Capital Management, and Velan Capital.